Gilead Sciences, Inc (GILD): Street Finally Waking Up

Currently, there are 1.25B common shares owned by the public and among those 1.24B shares have been available to trade.

The company’s stock has a 5-day price change of 6.68% and 26.53% over the past three months. GILD shares are trading 20.20% year to date (YTD), with the 12-month market performance up to 51.68% higher. It has a 12-month low price of $62.07 and touched a high of $111.03 over the same period. GILD has an average intraday trading volume of 7.09 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 10.04%, 16.16%, and 34.72% respectively.

Institutional ownership of Gilead Sciences, Inc (NASDAQ: GILD) shares accounts for 86.54% of the company’s 1.25B shares outstanding.

It has a market capitalization of $138.37B and a beta (3y monthly) value of 0.25. The stock’s trailing 12-month PE ratio is 299.35, while the earnings-per-share (ttm) stands at $0.37. The company has a PEG of 12.43 and a Quick Ratio of 1.20 with the debt-to-equity ratio at 1.21. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.18% over the week and 2.27% over the month.

Earnings per share for the fiscal year are expected to increase by 71.67%, and 5.46% over the next financial year. EPS should grow at an annualized rate of 24.09% over the next five years, compared to -38.21% over the past 5-year period.

Looking at the support for the GILD, a number of firms have released research notes about the stock. Deutsche Bank stated their Buy rating for the stock in a research note on February 18, 2025, with the firm’s price target at $120. DZ Bank coverage for the Gilead Sciences, Inc (GILD) stock in a research note released on February 13, 2025 offered a Buy rating with a price target of $108. Morgan Stanley was of a view on January 10, 2025 that the stock is Overweight, while BofA Securities gave the stock Buy rating on December 10, 2024, issuing a price target of $109. Wolfe Research on their part issued Outperform rating on November 15, 2024.

Most Popular

Related Posts